GRTX (GRTX)
Biotechnology
Sources: Yahoo Finance (quote, statistics) · SEC EDGAR (filings, insider trades, 13F holders) · company filings & press wires
Company overview
Live quote temporarily unavailable — press releases and news are still shown below.
Galera Therapeutics, Inc., a biopharmaceutical company, focuses on the development of a portfolio of small molecule dismutase (SOD) mimetics to improve radiotherapy in cancer. The company's lead product is tilarginine that is in Phase 1/2 trial of a pan-inhibitor of nitric oxide synthase to treat patients with highly resistant forms of breast cancer, including metaplastic breast cancer (MpBC) and other refractory subsets of triple-negative breast cancer (TNBC). It develops avasopasem manganese, a small molecule dismutase mimetic for the treatment of radiotherapy induced severe oral mucositis in patients with head and neck cancer (HNC). The company was incorporated in 2012 and is based in Malvern, Pennsylvania.
Peers in Healthcare
GRTX has no peer companies in this window.
Recent press releases
April 2026
Galera and Obsidian file merger plans; Obsidian presents OBX-115 Phase 2 data
# 📜 What This Document Is 📄 This document is a Form 425, which is a registration statement filed with the SEC. Think of it like a detailed blueprint showing how a company intends to merge with another company. 👉 This filing doesn't represent the merger itself, but rather the legal plan required
SEC filings
All filings →Insider trades
All insider trades →GRTX has no reported insider trades in the last 90 days.